Panobacumab
Monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.[1]
It is a fully human pentameric IgM antibody with a mouse J chain.[1]
![](http://upload.wikimedia.org/wikipedia/commons/thumb/f/f3/IgM.png/220px-IgM.png)
1: Base unit.
2: Heavy chains.
3: Light chains.
4: J chain.
5: Intermolecular disulfide bonds.
Development
Panobacumab is being developed by Aridis Pharmaceuticals. As of November 15th it is in phase 2 clinical trials. The originator was Berna Biotech.[2]
The mechanism of action is as a lipopolysaccharide inhibitor.[2]
References
- ^ a b International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ^ a b "Panobacumab - Aridis Pharmaceuticals - AdisInsight". Retrieved 15 November 2019.
- v
- t
- e
Monoclonal antibodies for infectious disease and toxins
Human |
|
---|
Human |
|
---|---|
Chimeric | |
Humanized |
Human |
|
---|---|
Mouse | |
Chimeric | |
Humanized |
Human | |
---|---|
Chimeric | |
Humanized |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e